These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 24261236)

  • 1. [Differential diagnosis and treatment of neurogenic and psychogenic dysuria in case of overactive bladder syndrome].
    Shvarts PG; Goriachev FK; Plotnikov AN; Savvin DIu; Popov SV
    Ter Arkh; 2013; 85(9):86-92. PubMed ID: 24261236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between the Overactive Bladder questionnaire (OAB-q) and urodynamic data of Parkinson disease patients affected by neurogenic detrusor overactivity during antimuscarinic treatment.
    Palleschi G; Pastore AL; Stocchi F; Bova G; Inghilleri M; Sigala S; Carbone A
    Clin Neuropharmacol; 2006; 29(4):220-9. PubMed ID: 16855424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Bladder deformations in neurogenic bladder secondary to cauda equina or conus medullaris lesion].
    Damphousse M; Hubeaux K; Weil M; Raibaut P; Lebreton F; Amarenco G
    Prog Urol; 2010 Jun; 20(6):450-7. PubMed ID: 20538210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vesicoureteral refulx in overactive bladder: medical resolution through botulin toxin injection.
    Arrabal-Polo MA; Nogueras-Ocaña M; Jiménez-Pacheco A; Palao-Yago F; Tinaut-Ranera J; López-León V; Zuluaga-Gómez A
    Arch Esp Urol; 2012 Nov; 65(9):844-8. PubMed ID: 23154611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Botulinum toxin type A in patients with overactive bladder].
    Krivoborodov GG; Vasil'ev AV; Shumilo DV; Ivanov AV; Tur EI
    Urologiia; 2010; (3):36-40. PubMed ID: 20734876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gabapentin treatment of neurogenic overactive bladder.
    Carbone A; Palleschi G; Conte A; Bova G; Iacovelli E; Bettolo CM; Pastore A; Inghilleri M
    Clin Neuropharmacol; 2006; 29(4):206-14. PubMed ID: 16855422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential diagnosis of overactive bladder in men.
    Blaivas JG; Marks BK; Weiss JP; Panagopoulos G; Somaroo C
    J Urol; 2009 Dec; 182(6):2814-7. PubMed ID: 19837417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Lower urinary tract dysfunctions in parkinsonian syndromes: a review by the Neuro-Urology Comittee of the French Association of Urology].
    Phé V; Caremel R; Bart S; Castel-Lacanal E; de Sèze M; Duchêne F; Even A; Gamé X; Loubat M; Scheiber Nogueira MC; Karsenty G;
    Prog Urol; 2013 Apr; 23(5):296-308. PubMed ID: 23545004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of neurogenic detrusor overactivity with botulinum toxin A: the first seven years.
    Stoehrer M; Wolff A; Kramer G; Steiner R; Lmöchner-Ernst D; Leuth D; Steude U; Ruebben H
    Urol Int; 2009; 83(4):379-85. PubMed ID: 19996642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urologic chronic pelvic pain syndrome.
    Martinez-Bianchi V; Halstater BH
    Prim Care; 2010 Sep; 37(3):527-46, viii. PubMed ID: 20705197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urodynamic testing in children: indications, technique, interpretation and significance.
    Drzewiecki BA; Bauer SB
    J Urol; 2011 Oct; 186(4):1190-7. PubMed ID: 21849190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravesical electromotive botulinum toxin type A administration--part II: Clinical application.
    Kajbafzadeh AM; Ahmadi H; Montaser-Kouhsari L; Sharifi-Rad L; Nejat F; Bazargan-Hejazi S
    Urology; 2011 Feb; 77(2):439-45. PubMed ID: 20800886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
    Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
    Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-neurogenic elimination disorders in children.
    Leclair MD; Héloury Y
    J Pediatr Urol; 2010 Aug; 6(4):338-45. PubMed ID: 20149751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective open label study of solifenacin for overactive bladder in children.
    Bolduc S; Moore K; Nadeau G; Lebel S; Lamontagne P; Hamel M
    J Urol; 2010 Oct; 184(4 Suppl):1668-73. PubMed ID: 20728124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hinman syndrome--an uncommon cause of recurrent urinary tract infections since childhood].
    Yossepowitch O; Neheman A; Gottesman T
    Harefuah; 2009 Nov; 148(11):769-71, 793, 792. PubMed ID: 20027980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prospective study of the clinical and urodynamic results of intradetrusor botulinum toxin injections for the treatment of neurogenic overactive bladder].
    Bentaleb Y; Castel-Lacanal E; Sallusto F; De Boissezon X; Malavaud B; Marque P; Rischmann P; Gamé X
    Prog Urol; 2008 Jul; 18(7):449-55. PubMed ID: 18602606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botulinum A toxin in the treatment of neurogenic detrusor overactivity: a consolidated field of application.
    Giannantoni A; Mearini E; Del Zingaro M; Santaniello F; Porena M
    BJU Int; 2008 Jul; 102 Suppl 1():2-6. PubMed ID: 18665971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of lower urinary tract symptoms in men with progressive neurological disease.
    Woderich R; Fowler CJ
    Curr Opin Urol; 2006 Jan; 16(1):30-6. PubMed ID: 16385198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.